APA (7th ed.) Citation

Wu, Y., Lee, V., Liam, C., Lu, S., Park, K., Srimuninnimit, V., . . . Mok, T. (2018). Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer (01695002), 126, 1. https://doi.org/10.1016/j.lungcan.2018.10.004

Chicago Style (17th ed.) Citation

Wu, Yi-Long, et al. "Clinical Utility of a Blood-based EGFR Mutation Test in Patients Receiving First-line Erlotinib Therapy in the ENSURE, FASTACT-2, and ASPIRATION Studies." Lung Cancer (01695002) 126 (2018): 1. https://doi.org/10.1016/j.lungcan.2018.10.004.

MLA (9th ed.) Citation

Wu, Yi-Long, et al. "Clinical Utility of a Blood-based EGFR Mutation Test in Patients Receiving First-line Erlotinib Therapy in the ENSURE, FASTACT-2, and ASPIRATION Studies." Lung Cancer (01695002), vol. 126, 2018, p. 1, https://doi.org/10.1016/j.lungcan.2018.10.004.